Integra Lifesciences Holdings Stock Analysis
| IART Stock | USD 15.38 0.58 3.92% |
Integra LifeSciences Holdings is overvalued with Real Value of 14.42 and Target Price of 15.88. The main objective of Integra LifeSciences stock analysis is to determine its intrinsic value, which is an estimate of what Integra LifeSciences Holdings is worth, separate from its market price. There are two main types of Integra LifeSciences' stock analysis: fundamental analysis and technical analysis.
The Integra LifeSciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Integra LifeSciences is usually not traded on Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday. Integra Stock trading window is adjusted to America/New York timezone.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. Integra Stock Analysis Notes
About 14.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.11. Some equities with similar Price to Book (P/B) outperform the market in the long run. Integra LifeSciences has Price/Earnings To Growth (PEG) ratio of 0.76. The entity recorded a loss per share of 6.54. The firm had not issued any dividends in recent years. Integra LifeSciences had 2:1 split on the 4th of January 2017. Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey. Integra Lifesciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 3800 people. To learn more about Integra LifeSciences Holdings call Jan Witte at 609 275 0500 or check out https://www.integralife.com.Integra LifeSciences Quarterly Total Revenue |
|
Integra LifeSciences Investment Alerts
| Integra LifeSciences appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 1.61 B. Net Loss for the year was (6.94 M) with profit before overhead, payroll, taxes, and interest of 932.82 M. | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Merit Medical Embosphere Microspheres Achieve CE Mark for Genicular Artery Embolisation to Treat Knee Osteoarthritis |
Integra LifeSciences Upcoming and Recent Events
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Integra Largest EPS Surprises
Earnings surprises can significantly impact Integra LifeSciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2003-04-25 | 2003-03-31 | 0.08 | 0.09 | 0.01 | 12 | ||
2002-08-01 | 2002-06-30 | 0.06 | 0.07 | 0.01 | 16 | ||
2002-05-08 | 2002-03-31 | 0.06 | 0.07 | 0.01 | 16 |
Integra LifeSciences Environmental, Social, and Governance (ESG) Scores
Integra LifeSciences' ESG score is a quantitative measure that evaluates Integra LifeSciences' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Integra LifeSciences' operations that may have significant financial implications and affect Integra LifeSciences' stock price as well as guide investors towards more socially responsible investments.
Integra LifeSciences Thematic Classifications
In addition to having Integra LifeSciences stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | Obamacare RepealLarge healthcare related equities associated with Obamacare | |
 | Baby Boomer ProspectsMega stocks, funds and ETFs that tend to appeal to people considering retirement from the work force |
Integra Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Soleus Capital Management, L.p. | 2025-06-30 | 1.4 M | Wellington Management Company Llp | 2025-06-30 | 1.3 M | Charles Schwab Investment Management Inc | 2025-06-30 | 1.2 M | Assenagon Asset Management Sa | 2025-06-30 | 1.2 M | Systematic Financial Management Lp | 2025-06-30 | 1.1 M | Neuberger Berman Group Llc | 2025-06-30 | 858.6 K | Millennium Management Llc | 2025-06-30 | 836.8 K | Deerfield Management Co | 2025-06-30 | 794.9 K | Voloridge Investment Management, Llc | 2025-06-30 | 749.8 K | Blackrock Inc | 2025-06-30 | 10.4 M | Vanguard Group Inc | 2025-06-30 | 7.6 M |
Integra Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.15 B.Integra Profitablity
The company has Profit Margin (PM) of (0.31) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.08 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.08.| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | 0.01 | 0.01 |
Management Efficiency
Integra LifeSciences has return on total asset (ROA) of 0.0243 % which means that it generated a profit of $0.0243 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3892) %, meaning that it created substantial loss on money invested by shareholders. Integra LifeSciences' management efficiency ratios could be used to measure how well Integra LifeSciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0.01 in 2025, whereas Return On Tangible Assets are likely to drop (0) in 2025. Total Current Liabilities is likely to gain to about 968.2 M in 2025. Liabilities And Stockholders Equity is likely to gain to about 4.2 B in 2025| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 20.07 | 21.07 | |
| Tangible Book Value Per Share | (9.86) | (9.37) | |
| Enterprise Value Over EBITDA | 18.03 | 10.98 | |
| Price Book Value Ratio | 1.13 | 1.07 | |
| Enterprise Value Multiple | 18.03 | 10.98 | |
| Price Fair Value | 1.13 | 1.07 | |
| Enterprise Value | 421.8 M | 442.9 M |
The strategic initiatives led by Integra LifeSciences' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Technical Drivers
As of the 19th of September, Integra LifeSciences retains the Risk Adjusted Performance of 0.0816, downside deviation of 3.05, and Market Risk Adjusted Performance of 0.1328. Integra LifeSciences technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Integra LifeSciences Price Movement Analysis
The output start index for this execution was eight with a total number of output elements of fifty-three. The Weighted Moving Average calculates a weight for each value in Integra LifeSciences price series with the more recent values given greater weights.
Integra LifeSciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Integra LifeSciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Integra LifeSciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Integra LifeSciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Integra LifeSciences Outstanding Bonds
Integra LifeSciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Integra LifeSciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Integra bonds can be classified according to their maturity, which is the date when Integra LifeSciences Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Integra LifeSciences Predictive Daily Indicators
Integra LifeSciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Integra LifeSciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Integra LifeSciences Corporate Filings
F4 | 2nd of September 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 18th of August 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 5th of August 2025 Other Reports | ViewVerify | |
8K | 31st of July 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 17th of July 2025 Other Reports | ViewVerify | |
| 9th of July 2025 Other Reports | ViewVerify | |
F4 | 7th of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 2nd of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Integra LifeSciences Forecast Models
Integra LifeSciences' time-series forecasting models are one of many Integra LifeSciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Integra LifeSciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Integra Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Integra LifeSciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Integra shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Integra LifeSciences. By using and applying Integra Stock analysis, traders can create a robust methodology for identifying Integra entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.01) | (0.01) | |
| Operating Profit Margin | 0.02 | 0.02 | |
| Gross Profit Margin | 0.55 | 0.67 |
Current Integra Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Integra analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Integra analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 15.88 | Hold | 12 | Odds |
Most Integra analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Integra stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Integra LifeSciences, talking to its executives and customers, or listening to Integra conference calls.
Integra Stock Analysis Indicators
Integra LifeSciences Holdings stock analysis indicators help investors evaluate how Integra LifeSciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Integra LifeSciences shares will generate the highest return on investment. By understating and applying Integra LifeSciences stock analysis, traders can identify Integra LifeSciences position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 276.4 M | |
| Long Term Debt | 1.2 B | |
| Common Stock Shares Outstanding | 77 M | |
| Total Stockholder Equity | 1.5 B | |
| Total Cashflows From Investing Activities | -390.8 M | |
| Tax Provision | -11.3 M | |
| Quarterly Earnings Growth Y O Y | 0.004 | |
| Property Plant And Equipment Net | 549.8 M | |
| Cash And Short Term Investments | 273.6 M | |
| Cash | 246.4 M | |
| Accounts Payable | 82.5 M | |
| Net Debt | 1.7 B | |
| 50 Day M A | 13.6912 | |
| Total Current Liabilities | 922.1 M | |
| Other Operating Expenses | 1.6 B | |
| Non Current Assets Total | 3 B | |
| Forward Price Earnings | 6.0533 | |
| Non Currrent Assets Other | 28.2 M | |
| Stock Based Compensation | 24.4 M |
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.